Two compounds capable of blocking a component of the immune system (NLRP3) that is involved in several inflammatory disorders are described in two papers published online this week in Nature Medicine. NLRP3 is part of a complex of proteins called the inflammasome, which drives the inflammatory response in several disorders including autoimmune disease, type 2 diabetes, Alzheimer’s disease, atherosclerosis and autoinflammatory disorders.
Vishwa Deep Dixit and colleagues report that β-hydroxybutyrate (BHB), a metabolite produced by the body in response to fasting, high-intensity exercise, caloric restriction or upon consumption of a low-carbohydrate ketogenic diet, can directly inhibit NLRP3. When BHB was packaged in a nanoparticle (to improve its bioavailability in vivo) it reduced inflammation in a mouse model of inflammatory disease, as did administration of a ketogenic diet, which elevated levels of BHB in the bloodstream. These findings suggest that the anti-inflammatory effects of fasting, a ketogenic diet or high-intensity exercise may, in part, be mediated by production of BHB and its inhibition of NLRP3.
In a separate study, Luke O’Neill, Matthew Cooper and colleagues describe a drug, MCC950, which directly inhibits NLRP3. The authors showed that MCC950 is effective at inhibiting inflammatory responses in human cells and in mouse models of autoimmune and autoinflammatory disease. This suggests that the compound may be used to treat a myriad of inflammatory diseases. Furthermore, the anti-inflammatory effects of MCC950 were not associated with inhibition of other components of the inflammasome complex that are important for control of infection.
Astronomy: How methane frost forms on Pluto’s mountain topsNature Communications
Ecology: Fast-growing trees die young and could affect carbon storageNature Communications
Epidemiology: US COVID-19 cases may be substantially underestimatedNature Communications
Environment: Atlantic Ocean contains more plastic than previously thoughtNature Communications